PLAQUE PSORIASIS

This study tests a new oral medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. About 731 adults will receive either the new drug, a placebo (inactive pill), or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal…

This study tests an experimental drug called JNJ-77242113 for people with moderate to severe plaque psoriasis, a skin condition causing red, scaly patches. About 684 adults will receive either the drug or a placebo to see if it clears or greatly improves their skin. The trial als…

This study looks at the long-term safety and effectiveness of the drug ESK-001 in people with plaque psoriasis who have already taken part in an earlier ESK-001 study. About 165 adults will receive the treatment and be monitored for side effects and how well their skin clears up.…

This study follows 550 adults in Germany with moderate-to-severe plaque psoriasis who are starting deucravacitinib, a daily pill. Researchers will check how well the drug clears skin and improves quality of life over 5 years in routine medical care. The goal is to see if results …

This study looks at the long-term safety and effectiveness of the drug ESK-001 for people with moderate to severe plaque psoriasis. About 1,680 adults who have already been in a prior ESK-001 study will take the drug for 24 weeks, then some may switch to a placebo to see how well…

This study checks the long-term safety and side effects of the drug TAK-279 in adults with moderate-to-severe plaque psoriasis. About 1,950 participants will take the drug for up to 208 weeks, with regular clinic visits. The goal is to see how well people tolerate the treatment o…

This study looks at how well deucravacitinib works for adults with moderate plaque psoriasis in everyday medical practice in China. Researchers will track 153 participants to see if their skin clears up and how much it improves. The goal is to understand the drug's real-world eff…

This study tests a new medicine called CT-P55 against the approved drug Cosentyx in 153 adults with moderate to severe plaque psoriasis. The goal is to see if CT-P55 works just as well and is as safe. Participants will receive either CT-P55 or Cosentyx, and doctors will measure c…

This study tests a drug called apremilast in Japanese children aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see if it can clear or nearly clear their skin by week 16. Participants must have tried topical treatments without success and be candidates for st…

This study tests an experimental drug called ORKA-001 in 80 adults with moderate-to-severe plaque psoriasis. Participants receive either the drug or a placebo to see if it can clear skin lesions. The main goal is to measure complete skin clearance at 16 weeks using a standard pso…

This study tests a new medication, JNJ-77242113, for people with plaque psoriasis in special areas like the scalp, genitals, palms, and soles. About 311 participants will receive either the drug or a placebo to see if it clears or greatly improves these stubborn patches. The goal…

This study tests a new oral medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. It compares the drug to a placebo and an existing treatment (ustekinumab) to see how well it clears skin lesions. About 752 adults with psoriasis are taking part, and the ma…

This study tests a new medicine called picankibart for people with plaque psoriasis who did not get good results from standard IL-17 antibody treatments. About 310 adults in China will receive either picankibart or an active control to see if switching helps clear skin and reduce…

This study tests a cream called tapinarof in 58 children aged 2 to 17 with plaque psoriasis. The goal is to see if the cream is safe and how it affects skin irritation. Children apply the cream daily, and doctors monitor for side effects and skin reactions.

This study looks at how the drug guselkumab affects the immune system in people with plaque or guttate psoriasis. About 25 adults with recent-onset guttate or plaque psoriasis will receive treatment. The goal is to understand changes in immune cells that cause psoriasis symptoms.

This study tests an experimental drug, JNJ-77242113, in 774 adults with moderate to severe plaque psoriasis. It compares the drug to a placebo and another approved treatment (deucravacitinib) to see how well it clears skin and reduces symptoms. The goal is to find a new oral opti…

This study tests whether a new daily pill, zasocitinib, works better than an existing treatment, deucravacitinib, for adults with moderate-to-severe plaque psoriasis. About 606 participants will take one of the two treatments daily for 16 weeks. The main goal is to see if zasocit…

This study looks at how safe the drug apremilast is for children aged 6 to 17 with mild to moderate plaque psoriasis. About 51 kids will take the drug and be monitored for side effects, growth, and development. The goal is to make sure the treatment is safe for younger patients.

This study tests whether a daily pill called IRX4204 can safely improve symptoms of mild to moderate plaque psoriasis in adults. About 20 participants will take the drug or a placebo for 28 days and have weekly checkups. The goal is to see if the drug clears or nearly clears skin…